Recent developments of aptamer-based lateral flow assays for point-of-care (POC) diagnostics

Anal Biochem. 2022 Oct 15:655:114874. doi: 10.1016/j.ab.2022.114874. Epub 2022 Aug 24.

Abstract

In the field of lateral flow assay (LFA), the application of aptamer as a bioreceptor has been implemented to overcome the limitations of antibodies, such as tedious in vivo processes, short shelf-life, and functionalization issues. To address these limitations aptamer-based LFA (ALFA) is preferred to antibody-based LFA that produces higher sensitivity and specificity. In principle, aptamers have a strong affinity towards their targets like small, large, and non-immunogenic molecules because of their high affinity, sensitivity, low dissociation constant, cost-effectiveness, and flexible nature. Thus, ALFA can be considered an efficient biosensor model for its superior portability, rapid detection with quick turnaround time, and usability by a non-technical person at any location with simple visual output. This review concisely overviews ALFA, its principles, formats, aptamer selection process, and biomedical applications. In addition, the critical components to design, develop, test, and amplify signals to create ALFA are discussed in brief. In addition, the aspects of conceptualization of ALFA product transforming from bench-side laboratory design and fabrication to commercial market are addressed in detail.

Keywords: Aptamer-based LFA; Aptamers; Lateral flow assay; SELEX; Sensors.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • Aptamers, Nucleotide*
  • Biological Assay
  • Biosensing Techniques*
  • Humans
  • Point-of-Care Systems
  • SELEX Aptamer Technique

Substances

  • Antibodies
  • Aptamers, Nucleotide